A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Ashbury, J E ^a,b   Levesque L E ^b,c   Beck, P A ^d   Aronson, K J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c Kingston   (Canada)

^d MINISTRY OF HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; LATENT PERIOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; REGISTER; SAMPLE SIZE; TREATMENT DURATION; BREAST TUMOR; CANADA; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG UTILIZATION; MIDDLE AGED; RISK FACTOR; STATISTICS; TIME;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; SASKATCHEWAN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 78650359436     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-90     Document Type: Article

References (36)

1. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992, 52:3796-3800.
2. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB Journal 1994, 8:654-660.
3. LaBella FS, Brandes LJ. Interaction of histamine and other bioamines with cytochromes P450: implications for cell growth modulation and chemopotentiation by drugs. Semin Cancer Biol 2000, 10:47-53. 10.1006/scbi.2000.0307, 10888271.
4. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25:1482-1488. 10.1200/JCO.2006.07.6356, 17372279.
5. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 2008, 22:20-27. 10.1177/0269881107082624, 18709700.
6. Coogan PF. Review of the epidemiological literature on antidepressant use and breast cancer risk. Expert Rev Neurother 2006, 6:1363-1374. 10.1586/14737175.6.9.1363, 17009923.
7. Canadian Cancer Society, Breast Cancer Statistics. , http://www.cancer.ca
8. National Cancer Institute, Surveillance Epidemiology and End Results (SEER). , http://seer.cancer.gov
9. Downey W, Stang M, Beck P, Osei W, Nichol J. Health services databases in Saskatchewan. Pharmacoepidemiology 2005, 295-310. New York: John Wiley & Sons Ltd, Strom BL.
10. Rothman KJ, Greenland S, Lash TL. Case-control studies. Modern Epidemiology 2008, 111-127. Philadelphia: Lippincott Williams & Wilkins, Rothman KJ, Greenland S, Lash TL.
11. Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002, 86:92-97. 10.1038/sj.bjc.6600013, 2746543, 11857018.
12. Tamim H, Boivin JF, Hanley J, Stang M, Collet JP. Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants. Pharmacoepidemiol Drug Saf 2006, 15:689-697. 10.1002/pds.1233, 16555372.
13. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst 1980, 65:559-569.
14. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. , http://www.whocc.no/atcddd/
15. Lee D, Bergman U. Studies of drug utilization. Pharmacoepidemiology 2005, 401-417. New York: John Wiley & Sons Ltd, Strom BL.
16. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989, 79:340-349. 10.2105/AJPH.79.3.340, 1349563, 2916724.
17. Budtz-Jorgensen E, Keiding N, Grandjean P, Weihe P. Confounder selection in environmental epidemiology: assessment of health effects of prenatal mercury exposure. Ann Epidemiol 2007, 17:27-35. 10.1016/j.annepidem.2006.05.007, 17027287.
18. Shapiro S. The role of automated record linkage in the postmarketing surveillance of drug safety: a critique. Clin Pharmacol Ther 1989, 46:371-386. 10.1038/clpt.1989.154, 2535647.
19. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999, 150:861-868.
20. Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000, 151:951-957.
21. Moorman PG, Grubber JM, Millikan RC, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 2003, 14:307-314. 10.1097/00001648-200305000-00010, 12859031.
22. Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 2005, 162:835-838. 10.1093/aje/kwi301, 16177141.
23. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Res Treat 2006, 95(2):131-140. 10.1007/s10549-005-9056-0, 16322894.
24. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 2009, 18:284-290. 10.1002/pds.1719, 2720762, 19226540.
25. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J. Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001, 54:728-734. 10.1016/S0895-4356(00)00354-1, 11438414.
26. Haque R, Enger SM, Chen W, Petitti DB. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett 2005, 221:61-65. 10.1016/j.canlet.2004.11.003, 15797628.
27. Gonzalez-Perez A, Garcia Rodriguez LA. Breast cancer risk among users of antidepressant medications. Epidemiology 2005, 16:101-105. 10.1097/01.ede.0000147103.92638.c0, 15613952.
28. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS. Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 2006, 94:1071-1078. 10.1038/sj.bjc.6603017, 2361224, 16523201.
29. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. Incidence of cancer and antidepressant medication: record linkage study. Int J Cancer 2010, 126:285-296. 10.1002/ijc.24537, 19739257.
30. Rawson NS, Robson DL. Concordance on the recording of cancer in the Saskatchewan Cancer Agency Registry, hospital charts and death registrations. Can J Public Health 2000, 91:390-393.
31. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995, 142:1103-1112.
32. West SL, Strom BL, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. Pharmacoepidemiology 2005, 709-765. New York: John Wiley and Sons Ltd, Strom BL.
33. Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003, 32:961-966. 10.1093/ije/dyg155, 14681256.
34. Loosbrock DL, Tomlin ME, Robinson RL, Obenchain RL, Croghan TW. Appropriateness of prescribing practices for serotonergic antidepressants. Psychiatr Serv 2002, 53:179-184. 10.1176/appi.ps.53.2.179, 11821548.
35. Jacobs JR, Bovasso GB. Early and chronic stress and their relation to breast cancer. Psychol Med 2000, 30:669-678. 10.1017/S0033291799002020, 10883721.
36. Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 1998, 90:1888-1893. 10.1093/jnci/90.24.1888, 9862626.